Open AccessReal‐life effectiveness of a new allergic rhinitis therapy (MP29‐02*) in Sweden
Author(s) -
Stjärne Pär,
Strand Victoria,
Theman Kaj,
Kuhl Hans Christian,
Ehnhage Anders
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s4-p37
Subject(s) - medicine , fluticasone propionate , visual analogue scale , pediatrics , population , clinical trial , physical therapy , asthma , environmental health
Background Over one quarter of individuals in Sweden report suffering from allergic rhinitis (AR), placing a considerable burden on both sufferers and society [1]. In clinical trials MP2902* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) provided complete/near complete symptom control in 1 of 6 moderate/severe seasonal AR (SAR) patients [2] and complete relief in 7 of 10 mild/ moderate perennial AR (PAR) patients [3]. This study aimed to assess the effectiveness of MP29-02* in routine clinical practice.